Trial Profile
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK0941 After Multiple Daily Administration in Subjects With Type 2 Diabetes.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs MK 0941 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Merck Sharp & Dohme Corp.
- 10 Jul 2012 Primary endpoints amended as reported by ClinicalTrials.gov.
- 30 May 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Apr 2009 New trial record